Axel Grothey, MD
| Profession: | Professor of Oncology; Consultant, Medical Oncology, Mayo Clinic |
| Member since: | 2006 Dec 18 |
Recent Posts
Capecitabine and Oxaliplatin for Gastric Cancer After Gastrectomy
Dr. Axel Grothey: Progress Finally—New Adjuvant Therapy for Advanced Colorectal Cancer
Use of CT-PET Before Colon Adenocarcinoma Resection?
Adjuvant Chemotherapy in High-Risk Stage II Colon Cancer?
Role for PET/CT in Follow-Up of Resected Oligometastatic CRC?
XRT Needed in Addition to FOLFOX in Resected Cecal Cancer?
Adjuvant Chemo for Familial Adenomatous Polyposis?
Recurrence Risk Assay Validated for Stage II Colon Cancer
Vandetanib Effective in Advanced Medullary Thyroid Cancer
Introducing "Ask the Expert"
Low Absolute Risk of Adenocarcinoma in Barrett's Esophagus
Laparoscopic Liver Resection Headed for Mainstream
Everolimus Improved PFS in Advanced Neuroendrocrine Pancreatic Cancer
Mutant KRAS Associated With Lung, Brain Mets in CRC
Dr. Axel Grothey: The Failure of Clinical Trials of Adjuvant Therapy in Colorectal Cancer Is Sobering
Axel Grothey, MD: My Approach to Metastatic Colorectal Cancer
Bio
Biographical Sketch:
Axel Grothey is a Professor of Oncology and Consultant in the Division of Medical Oncology in the Department of Oncology at the Mayo Clinic in Rochester, MN. He is the Vice Chair of the North Central Cancer Treatment Group (NCCTG) and the co-chair of the NCCTG GI committee.
After receiving his medical degree from Ruhr-University Bochum in Germany, Dr. Grothey completed his residency in internal medicine at the West-German Tumor Center at the University of Essen. He also completed residencies in pathology and internal medicine at prestigious universities in Germany and was awarded a fellowship in the Department of Hematology-Oncology at the University of Bochum. Subsequently, Dr. Grothey was awarded a postdoctoral research fellowship to address the effect of kinase-mediated signaling on the actin cytoskeleton and phenotypic properties of cancer cells at the MD Anderson Cancer Center at the University of Texas.
Dr. Grothey is a member of the Association of German Internists, the American Association of Cancer Research, the European Association for Cancer Research, the American Society for Cell Biology, the American Society of Clinical Oncology, and the European Society for Medical Oncology. He serves on the review board of numerous professional journals. In addition, he is widely published in many peer-reviewed journals. Dr. Grothey’s major areas of clinical interest are GI malignancies, in particular, colorectal cancer, unknown primaries, and neuroendocrine tumors.
Positions:
Professor of Oncology, Mayo Clinic
Consultant, Division of Medical Oncology, Mayo Clinic
Degree:
Ruhr-University Bochum, MD
Postgraduate Training:
Postdoctoral research fellow, (PD McCrea, PhD), Department of Biochemistry and Molecular Biology, MD Anderson Cancer Center
Postdoctoral fellow, Department of Hematology-Oncology, Ruhr-University Bochum
Resident, internal medicine, Department of Internal Medicine, Ruhr-University Bochum
Resident, Institute of Pathology, University of Duisburg-Essen
Resident, internal medicine, West-German Tumor Center, University of Duisburg-Essen
Board Certifications:
ECFMG and USMLE 1, 2, and 3
German Board of Internal Medicine
German Board of Hematology/Oncology
European Certificate in Medical Oncology
European Society of Medical Oncology
Educational Commission for Foreign Medical Graduates
Clinical Interests:
Colorectal cancer, neuroendocrine tumors, unknown primaries
Sign up for our newsletters
Too busy to follow cancer's top stories? Sign-up for one or more of our leading newsletters -- delivered weekly to your inbox.